Bezafibrate

CARDIOVASCULAR SYSTEM

Key facts

Bezafibrate is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1978. DrugCentral lists 7 molecular targets, including FABP2, PPARD and Fabp1. Recorded indications include Hypercholesterolemia and Hyperlipidemia.

• Molecular targets: FABP2, PPARD, Fabp1 and PPARA (7 listed in DrugCentral).
• Indications: Hypercholesterolemia and Hyperlipidemia.
• ATC code: C10AB02 (Fibrates).
• Molecular formula: C19H20ClNO4; molecular weight 361.82 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Hypercholesterolemia
• Hyperlipidemia

Contraindications (1)

• End stage renal disease

Mechanism & targets

Molecular targets (7)

Target	Gene	Action	Activity
Fatty acid-binding protein, intestinal	FABP2	unknown	Ki 4.48
Peroxisome proliferator-activated receptor delta	PPARD	unknown	EC50 4.45
Fatty acid-binding protein, liver	Fabp1	unknown	Ki 4.35
Peroxisome proliferator-activated receptor alpha	PPARA	agonist	EC50 4.30
Peroxisome proliferator-activated receptor gamma	PPARG	unknown	EC50 4.18
Lipoprotein lipase	LPL	unknown	—
3-hydroxy-3-methylglutaryl-coenzyme A reductase	HMGCR	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1978-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
C10AB02	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › Fibrates

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Pancreatitis acute	67.4
Diverticular perforation	60.8
Hepatic function abnormal	60.3
Hypertriglyceridaemia	57.0
Renal impairment	50.8
Acute kidney injury	49.5
Vascular stent stenosis	48.9
Coronary artery thrombosis	46.4
Arterial stenosis	43.2
Helicobacter gastritis	42.7
Rhabdomyolysis	42.4
Cor pulmonale acute	42.2

Chemical structure

• Molecular formula: C₁₉H₂₀ClNO₄
• Molecular weight: 361.82 g/mol
• CAS number: 41859-67-0
• InChIKey: IIBYAHWJQTYFKB-UHFFFAOYSA-N
• PubChem CID: 39042

CC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Bezafibrate used for?

DrugCentral lists the following indications for Bezafibrate: Hypercholesterolemia and Hyperlipidemia.

How does Bezafibrate work?

Its molecular targets in DrugCentral include FABP2, PPARD, Fabp1 and PPARA (agonist).

When was Bezafibrate first approved?

Bezafibrate was first approved by the YEAR INTRODUCED in 1978.

What is the chemical formula of Bezafibrate?

Bezafibrate has the molecular formula C19H20ClNO4 and a molecular weight of 361.82 g/mol.

Sources

• DrugCentral drug card 362 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL264374 — compound record and bioactivity
• PubChem CID 39042 — chemical identifiers
• DrugBank DB01393 — drug record
• FDA UNII Y9449Q51XH — substance identity
• UniProt P12104 (FABP2) — target protein
• UniProt Q03181 (PPARD) — target protein
• UniProt Q07869 (PPARA) — target protein
• UniProt P37231 (PPARG) — target protein
• UniProt P06858 (LPL) — target protein
• UniProt P04035 (HMGCR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.